Prothrombotic effect of Rofecoxib in a murine venous thrombosis model

Thrombosis Research

Volumn 122, Issue 5, 2008, Pages 668-673

  Nagai, Nobuo ^a   Hoylaerts, Marc F ^a   Gallacher, David J ^b   Lu, Hua Rong ^b   Lijnen, H Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

COX 2; Obesity; Rofecoxib; Thrombosis; Vioxx

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; FERROUS CHLORIDE; ROFECOXIB; THROMBIN ANTITHROMBIN COMPLEX; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL ARTERY; JUGULAR VEIN; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VEIN OCCLUSION; VEIN THROMBOSIS; WILD TYPE;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; JUGULAR VEINS; LACTONES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; OBESITY; PLATELET AGGREGATION; SULFONES; THROMBOSIS; VENOUS THROMBOSIS;

EID: 49549098367     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.04.016     Document Type: Article

References (30)

1. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
2. Smith W.L., and Marnett L.J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1083 (1991) 1-17
3. Raz A., Wyche A., Siegel N., and Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 263 (1988) 3022-3028
4. Wu K.K. Cyclooxygenase-2 induction in congestive heart failure: friend or foe?. Circulation 98 (1998) 95-96
5. Vane J.R., and Botting R.M. Pharmacodynamic profile of prostacyclin. Am J Cardiol 75 (1995) 3A-10A.
6. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
7. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
8. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
9. Kerr D.J., Dunn J.A., Langmann M.J., Smith J.L., Midgley R.S., Stanley A., et al. VICTOR Trial Group. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357 (2007) 360-369
10. Cheng Y., Austin S.C., Rocca B., Koller B.H., Coffman T.M., Grosser T., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296 (2002) 539-541
11. Abdollahi M., Cushman M., and Rosendaal F.R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 89 (2003) 493-498
12. Stein P.D., Beemath A., and Olson R.E. Obesity as a risk factor in venous thromboembolism. Am J Med 118 (2005) 978-980
13. Darvall K.A., Sam R.C., Silverman S.H., Bradbury A.W., and Adam D.J. Obesity and thrombosis. Eur J Vasc Endovasc Surg 33 (2007) 223-233
14. Nemmar A., Hoet P.H., Vandervoort P., Dinsdale D., Nemery B., and Hoylaerts M.F. Enhanced peripheral thrombogenicity after lung inflammation is mediated by platelet-leukocyte activation: role of P-selectin. J Thromb Haemost 5 (2007) 1217-1226
15. Fay W.P., Parker A.C., Ansari M.N., Zheng X., and Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 93 (1999) 1825-1830
16. Declerk P.J., Verstreken M., and Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 74 (1995) 1035-1039
17. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., et al. APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (2006) 1674-1682
18. Furberg C.D., Psaty B.M., and FitzGerald G.A. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 111 (2005) 249
19. Solomon S.D. Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr Opin Cardiol 21 (2006) 613-617
20. Hermann M., and Ruschitzka F. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Ann Med 39 (2007) 18-27
21. Marwali M.R., and Mehta J.L. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thromb Haemost 96 (2006) 401-406
22. Mukherjee D. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Thromb Haemost 96 (2006) 407-412
23. Weber A.A., Hohlfeld T., and Harder S. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments against. Thromb Haemost 96 (2006) 413-416
24. Linton M.F., and Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 13 (2002) 497-504
25. Belton O., Byrne D., Kearney D., Leaky A., and Fitzgerald D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
26. Mitchell J.A., Lucas R., Vojnovic I., Hasan K., Pepper J.R., and Warner T.D. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. Faseb J 20 (2006) 2468-2475
27. Ghosh M., Wang H., Ai Y., Romeo E., Luyendyk J.P., Peters J.M., et al. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARS activation. J Exp Med 204 (2007) 2053-2061
28. -/- mice. J Mol Med 85 (2007) 623-633
29. Efstathiou J.A., Sampson D.A., Levine Z., Rohan R.M., Zurakowski D., Folkman J., et al. Nonsteroidal anti-inflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 83 (2005) 171-181
30. N. Nagai, M.F. Hoylaerts, A.C.A. Cleuren, B.J.M. Van Vlijmen, H.R. Lijnen. Obesity promotes injury induced femoral artery thrombosis in mice. Thrombos Res (in press).